Do you perform biomarker-based screening for AL amyloidosis in patients with newly diagnosed MGUS?
If so, what is your approach to laboratory and clinical testing?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · University of Kansas Medical Center
Answered on
No, unless the patient has signs and symptoms or imaging studies that suggest systemic Amyloidosis.
Join for free or sign in to see the full answer